SCHEMBL13650531

SCHEMBL13650531

Nc1nc(NCC2CCN2)c2c(n1)C(c1ccccc1)CCC2

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 4/20 0.53
▸ HRH4 Q9H3N8 3/20 0.53
▸ APP P05067 1/20 0.39
▸ HRH2 P25021 1/20 0.37
▸ EEF2K O00418 1/20 0.35
▸ EHMT2 Q96KQ7 1/20 0.34
▸ ACHE P22303 1/20 0.33
▸ HTR2B P41595 1/20 0.32
▸ PRKCI P41743 1/20 0.32
▸ PSEN1 P49768 2/20 0.32
▸ PSEN2 P49810 2/20 0.32
▸ APH1B Q8WW43 2/20 0.32
▸ NCSTN Q92542 2/20 0.32
▸ APH1A Q96BI3 2/20 0.32
▸ PSENEN Q9NZ42 2/20 0.32
▸ TNK2 Q07912 1/20 0.31
▸ PRMT5 O14744 1/20 0.31
▸ CHUK O15111 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13650537 0.94 HRH4 (0.52) HRH3HRH4APPHRH2EEF2K
SCHEMBL13650618 0.94 HRH4 (0.52) HRH3HRH4APPHRH2EEF2K
SCHEMBL13650535 0.93 HRH4 (0.53) HRH3HRH4APPHRH2EEF2K
SCHEMBL13650647 0.89 HRH3 (0.51) HRH3HRH4APPHRH2EEF2K
SCHEMBL13650470 0.86 HRH4 (0.57) HRH3HRH4APPHRH2EEF2K
SCHEMBL13650456 0.85 HRH3 (0.53) HRH3HRH4APPHRH2EEF2K
SCHEMBL13650465 0.84 HRH4 (0.53) HRH3HRH4APPHRH2EHMT2
SCHEMBL13657250 0.84 HRH4 (0.53) HRH3HRH4APPHRH2EHMT2
SCHEMBL13650475 0.83 HRH4 (0.52) HRH3HRH4APPEHMT2HTR2B
SCHEMBL13650557 0.83 HRH4 (0.47) HRH3HRH4APPHRH2EEF2K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 — — WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH3 3555/4885HRH4 3370/4885APP 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback